Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Raben

Showing results (121-130 of 161) with videos related to

Pageof 17
Sort By:
The Lancet. Oncology|November 10, 2009
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalJames A Bonner, Paul M Harari, Jordi Giralt, et al.
Journal of Cancer Science & Therapy|May 28, 2010
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia FunctionAmanda Gatesman Ammer, Laura C Kelley, Karen E Hayes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levelsBarbara A Helfrich, David Raben, Marileila Varella-Garcia, et al.
Oncogene|August 17, 2019
CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8<sup>+</sup> T-cell responses by upregulating MHC-I expressionJoseph A Westrich, Daniel W Vermeer, Alexa Silva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinomaChristine H Chung, Qiang Zhang, Christina S Kong, et al.
International Journal of Radiation Oncology, Biology, Physics|June 15, 2014
Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancerD W Nathan Kim, L Chinsoo Cho, Christopher Straka, et al.
Head & Neck|October 30, 2014
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinomaVasiliki A Papadimitrakopoulou, Steven J Frank, Ezra W Cohen, et al.
Nature Medicine|March 12, 2013
Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositisGangwen Han, Li Bian, Fulun Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2020
PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental ModelsAriel L Hernandez, Christian D Young, Li Bian, et al.
International Journal of Radiation Oncology, Biology, Physics|May 24, 2016
Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG ExperienceVoichita Bar-Ad, Qiang Ed Zhang, Paul M Harari, et al.
Pageof 17

Showing results (121-130 of 161) with videos related to

Sort By:
Pageof 17
The Lancet. Oncology|November 10, 2009
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalJames A Bonner, Paul M Harari, Jordi Giralt, et al.
Journal of Cancer Science & Therapy|May 28, 2010
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia FunctionAmanda Gatesman Ammer, Laura C Kelley, Karen E Hayes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levelsBarbara A Helfrich, David Raben, Marileila Varella-Garcia, et al.
Oncogene|August 17, 2019
CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8<sup>+</sup> T-cell responses by upregulating MHC-I expressionJoseph A Westrich, Daniel W Vermeer, Alexa Silva, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinomaChristine H Chung, Qiang Zhang, Christina S Kong, et al.
International Journal of Radiation Oncology, Biology, Physics|June 15, 2014
Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancerD W Nathan Kim, L Chinsoo Cho, Christopher Straka, et al.
Head & Neck|October 30, 2014
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinomaVasiliki A Papadimitrakopoulou, Steven J Frank, Ezra W Cohen, et al.
Nature Medicine|March 12, 2013
Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositisGangwen Han, Li Bian, Fulun Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2020
PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental ModelsAriel L Hernandez, Christian D Young, Li Bian, et al.
International Journal of Radiation Oncology, Biology, Physics|May 24, 2016
Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG ExperienceVoichita Bar-Ad, Qiang Ed Zhang, Paul M Harari, et al.
Pageof 17